On Friday, Autolus Therapeutics plc ADR (NASDAQ: AUTL) opened lower -7.43% from the last session, before settling in for the closing price of $2.69. Price fluctuations for AUTL have ranged from $2.69 to $7.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 190.29% over the last five years. Company’s average yearly earnings per share was noted 24.87% at the time writing. With a float of $236.67 million, this company’s outstanding shares have now reached $266.12 million.
The firm has a total of 463 workers. Let’s measure their productivity. In terms of profitability, gross margin is 51.97%, operating margin of -1739.83%, and the pretax margin is -2172.6%.
Autolus Therapeutics plc ADR (AUTL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Autolus Therapeutics plc ADR is 11.06%, while institutional ownership is 56.29%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 24.87% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Check out the current performance indicators for Autolus Therapeutics plc ADR (AUTL). In the past quarter, the stock posted a quick ratio of 13.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 65.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Analysing the last 5-days average volume posted by the [Autolus Therapeutics plc ADR, AUTL], we can find that recorded value of 2.17 million was better than the volume posted last year of 1.48 million. As of the previous 9 days, the stock’s Stochastic %D was 9.26%. Additionally, its Average True Range was 0.24.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 1.57%, which indicates a significant decrease from 4.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.01% in the past 14 days, which was lower than the 71.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.59, while its 200-day Moving Average is $4.18. Now, the first resistance to watch is $2.66. This is followed by the second major resistance level at $2.82. The third major resistance level sits at $2.93. If the price goes on to break the first support level at $2.39, it is likely to go to the next support level at $2.28. Should the price break the second support level, the third support level stands at $2.12.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
There are currently 266,094K shares outstanding in the company with a market cap of 662.64 million. Presently, the company’s annual sales total 1,700 K according to its annual income of -208,380 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -58,270 K.
